要约收购
Search documents
亚振家居股份有限公司董事会关于自然人吴涛要约收购事宜致全体股东报告书
Shang Hai Zheng Quan Bao· 2025-06-23 19:57
上市公司名称:亚振家居股份有限公司 登录新浪财经APP 搜索【信披】查看更多考评等级 注册地址:江苏省南通市如东县曹埠镇亚振桥 办公地址:江苏省南通市如东县曹埠镇亚振桥 股票上市地点:上海证券交易所 联系人:黄周斌 联系电话:0513-84296002 收购人名称:吴涛 通讯地址:济南市历城区**** 独立财务顾问名称:民生证券股份有限公司 股票简称:*ST亚振 股票代码:603389 董事会报告书签署日期:二〇二五年六月 有关各方及联系方式 上市公司名称:亚振家居股份有限公司 联系地址:江苏省南通市如东县曹埠镇亚振桥 联系地址:中国(上海)自由贸易试验区浦明路8号 联系人:赵勇、丁小园 联系电话:021-80508627 董事会声明 一、本公司全体董事确信本报告不存在任何虚假记载、误导性陈述或重大遗漏,并对其内容的真实性、 准确性、完整性负个别的和连带的责任; 二、本公司全体董事已履行诚信义务,向股东所提出的建议是基于公司和全体股东的整体利益客观审慎 做出的; 三、本公司全体董事没有任何与本次收购相关的利益冲突。 释义 本报告书中,除非另有说明,下列简称具有如下特定意义: ■ 注:本报告书中部分合计数与各分 ...
*ST亚振: 关于吴涛要约收购亚振家居股份有限公司之独立财务顾问报告
Zheng Quan Zhi Xing· 2025-06-23 11:40
民生证券股份有限公司 关于 吴涛 要约收购 亚振家居股份有限公司 之 独立财务顾问报告 独立财务顾问 签署日期:2025 年 6 月 独立财务顾问声明 民生证券股份有限公司(以下简称"民生证券"或"本独立财务顾 问 " ) 接 受 亚 振 家 居 股 份 有 限 公 司 ( 以 下 简 称 " *ST 亚 振 " 或 " 上 市 公 司")的委托,担任本次要约收购的独立财务顾问,并出具独立财务顾问报 告(以下简称"本报告"或"本独立财务顾问报告")。 截至本报告签署日,*ST亚振已向本独立财务顾问提供*ST亚振财务报 告、相关方股票买卖查询情况以及相关承诺函等资料,并将其取得的全部备 查文件转交给本独立财务顾问。*ST亚振承诺已无保留地将其取得的全部备 查文件提供给民生证券,对提供给民生证券除备查文件以外的一切书面材 料、文件或口头证言的真实性、准确性和完整性负责,并不存在虚假记载、 误导性陈述或重大遗漏。 除*ST亚振提供及转交的全部资料外,本报告所依据的其他信息均来自 公开渠道。鉴于未能取得进一步证明文件作为依据且未能履行相关核查程 序,本独立财务顾问无法对《要约收购报告书》及其备查文件内容和通过公 开渠 ...
*ST亚振: 关于股票交易停牌核查结果暨复牌的公告
Zheng Quan Zhi Xing· 2025-06-20 09:45
亚振家居股份有限公司 证券代码:603389 证券简称:*ST 亚振 公告编号:2025-041 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏,并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: ? 证券停复牌情况:适用 因重大事项,本公司的相关证券复牌情况如下: 停牌 证券代码 证券简称 停复牌类型 停牌起始日 停牌终止日 复牌日 期间 ? 公司股票于 2025 年 5 月 6 日至 6 月 11 日连续二十六个交易日内日收盘价格涨 幅偏离值累计达到 107.83%,多次触及股票交易异常波动。公司股票短期涨幅与同 期上证指数、家具制造业存在严重偏离。为维护投资者利益,公司就股票交易情 况进行了核查。公司郑重提醒广大投资者,公司股价可能存在短期涨幅较大后下 跌的风险,请投资者务必充分了解二级市场交易风险,切实提高风险意识,理性 决策、审慎投资。 ? 生产经营风险。公司 2024 年度经审计的扣除非经常性损益后的净利润为负值, 且扣除与主营业务无关的业务收入和不具备商业实质的收入后的营业收入低于 3 亿元,触及《上海证券交易所股票上市规则》第 9.3.2 条第一 ...
*ST亚振: 关于吴涛先生要约收购公司股份的第一次提示性公告
Zheng Quan Zhi Xing· 2025-06-20 09:37
截至要约收购报告书签署日,吴涛先生及其一致行动人已通过股份协议转让 收购公司 29.99996%股份及其对应的表决权,上市公司控股股东、实际控制人变 更为吴涛先生。同时,根据亚振投资及高伟先生、户美云女士、高银楠女士与吴 涛先生于 2025 年 4 月 24 日签署的《股份转让协议一之补充协议》约定,上海亚 振投资有限公司(以下简称"亚振投资")及其一致行动人上海浦振投资管理有 限公司(以下简称"浦振投资")、上海恩源投资管理有限公司(以下简称"上 海恩源")不可撤销地承诺以其持有的公司共计 53,771,753 股股份(占上市公司 总股本的 20.4648%)有效申报预受要约,并自前述股份协议转让完成之日起至 本次要约收购完成之日止,放弃各自预受要约股份的表决权。 吴涛先生拟通过本次部分要约收购增加对上市公司的持股比例,进一步巩固 其对公司的控制权。 证券代码:603389 证券简称:*ST 亚振 公告编号:2025-042 亚振家居股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏,并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 本次要约收购期 ...
17个涨停板!“妖股”*ST亚振股价狂涨导致停牌
Xi Niu Cai Jing· 2025-06-19 07:08
6月12日,亚振家居(证券简称*ST亚振)因股价近期大幅异常波动,于6月12日起停牌核查。GPLP犀牛财经注意到,亚振家居股票在5月6日至6月11日的连 续26个交易日内,17次触及涨停,日收盘价格涨幅偏离值累计高达107.83%,多次触及交易异常波动情形。 值得注意的是,亚振家居基本面并不支撑如此涨幅。该公司因连续3年亏损,且2024年营业收入低于3亿元,于4月30日被证监会实施退市风险警示 (*ST),经营状况严峻。 据了解,此轮股价狂飙的背景是亚振家居新实控人吴涛的入主。4月24日,亚振家居发布公告称,自然人吴涛计划通过"协议转让+部分要约收购"的方式取得 亚振家居控制权。随后,吴涛及其一致行动人范伟浩以4.48亿元总价、每股5.68元的价格,从原控股股东亚振投资处受让了公司30%的股权(其中吴涛占 24.54%)。该股权转让已于5月底完成过户,亚振家居控股股东及实际控制人正式变更为吴涛。 6月5日,吴涛进一步发出部分要约收购计划,拟在6月10日至7月9日期间,以同样的5.68元/股价格,向其他股东收购约5517.79万股(占总股本的21%)。若 收购成功,吴涛持股比例将升至51%,进一步巩固控制权。 ...
湖北济川药业股份有限公司关于曹飞先生要约收购公司股份的第一次提示性公告
Shang Hai Zheng Quan Bao· 2025-06-16 20:47
Core Viewpoint - The announcement details Mr. Cao Fei's tender offer to acquire shares of Hubei Jichuan Pharmaceutical Co., Ltd., with a focus on the acquisition's timeline, purpose, and conditions [2][3][4]. Group 1: Tender Offer Details - The tender offer is valid from June 18, 2025, to July 17, 2025, with specific conditions regarding the withdrawal of acceptance in the last three trading days [2][6][9]. - Mr. Cao Fei intends to acquire 350,841,357 shares, representing 38.06% of the total share capital of the company, at a price of 26.93 yuan per share [5][6]. - The payment method for the tender offer will be in cash [4][5]. Group 2: Purpose of the Tender Offer - The tender offer is a result of a share transfer agreement between Mr. Cao Longxiang and Mr. Cao Fei, where 10.10% of Jiangsu Jichuan Holding Group Co., Ltd. was transferred to Mr. Cao Fei for 10.1 million yuan, indicating a family restructuring of shareholding [2][3]. - The acquisition aims to fulfill the legal obligation for a comprehensive tender offer, and it does not intend to terminate the listing status of Jichuan Pharmaceutical [3]. Group 3: Procedures for Acceptance - Shareholders can submit their acceptance of the tender offer through designated securities companies during the offer period, with specific codes for the tender offer [7][8]. - Accepted shares will be temporarily held by China Securities Depository and Clearing Corporation Limited during the offer period, and shareholders cannot transfer these shares until the withdrawal process is completed [8][10]. Group 4: Additional Information - The company will provide updates on the progress of the tender offer and will issue a results announcement after the offer period ends [6][13]. - Investors seeking detailed information can refer to the tender offer report published on June 16, 2025, on the Shanghai Stock Exchange website [15].
父子股权调整触发要约收购,曹飞欲斥资94亿收购济川药业3.5亿股
Huan Qiu Lao Hu Cai Jing· 2025-06-16 13:31
Group 1 - The actual controller of Jichuan Pharmaceutical, Cao Longxiang, is transferring shares to his son, Cao Fei, which triggers a mandatory tender offer for the company [1][2] - Cao Fei will acquire 351 million shares, representing 38.06% of the total issued shares, with a maximum transaction value of 9.448 billion yuan [1][2] - Following the share transfer, Cao Fei's stake in Jichuan Holdings will increase to 60%, allowing him to indirectly control 517 million shares of Jichuan Pharmaceutical, exceeding the 30% threshold for a mandatory tender offer [2] Group 2 - Jichuan Pharmaceutical is facing significant pressure, with revenue and net profit declining for four consecutive quarters due to price cuts from centralized procurement [4] - In 2024, the company expects to achieve revenue of 8.017 billion yuan, a year-on-year decrease of 16.96%, and a net profit of 2.532 billion yuan, down 10.32% [4] - The company's sales expenses are high at 2.954 billion yuan, accounting for 36.85% of total revenue, while R&D expenses are only 445 million yuan, representing 5.55% of total revenue [4]
新股发行及今日交易提示-20250616
HWABAO SECURITIES· 2025-06-16 08:50
Group 1: New Stock Offerings - Jichuan Pharmaceutical (600566) has a tender offer period from June 18, 2025, to July 17, 2025[1] - *ST Yazhen (603389) has a tender offer period from June 10, 2025, to July 9, 2025[1] Group 2: Delisting Information - *ST Gongzhi (000584) will enter the delisting arrangement period starting June 20, 2025[1] - Delisting Haiyue (600387) has 14 trading days remaining until the last trading day[1] - Renle Tui (002336) has 13 trading days remaining until the last trading day[1] - Delisting Longyu (603003) has 10 trading days remaining until the last trading day[1] - Delisting Pengbo (600804) has 10 trading days remaining until the last trading day[1] - Longjin Tui (002750) has 8 trading days remaining until the last trading day[1] Group 3: Abnormal Fluctuations - Lianhua Technology (002250) reported severe abnormal fluctuations[1] - ST Kailin (002425) reported abnormal fluctuations[1] - ST Xianfeng (002141) reported abnormal fluctuations[1] - ST Shihuan (000518) reported abnormal fluctuations[1]
济川药业: 湖北济川药业股份有限公司关于收到要约收购报告书的提示性公告
Zheng Quan Zhi Xing· 2025-06-15 10:17
Core Viewpoint - The company has received a takeover offer from Mr. Cao Fei, which triggers a mandatory general offer due to the increase in shareholding above 30% [2][4]. Summary by Sections Offer Details - The offer price is set at 26.93 yuan per share, with a total of 350,841,357 shares being offered, representing 38.06% of the company's issued shares [4][5]. - The offer period lasts for 30 days, from June 18, 2025, to July 17, 2025, during which shareholders cannot withdraw their acceptance in the last three trading days [7]. Shareholding Changes - Mr. Cao Longxiang plans to transfer 10.10% of his shares in Jiangsu Jichuan Holding Group to his son, Mr. Cao Fei, making Mr. Cao Fei the controlling shareholder of Jichuan Holding with 60% ownership [2][4]. - Following the transfer, both Mr. Cao Fei and Mr. Cao Longxiang will be the joint actual controllers of the listed company, ensuring that the company's independence remains unaffected [2][4]. Financial Arrangements - The total maximum funding required for the offer is 18.95 billion yuan, with at least 20% of this amount deposited as a performance guarantee [6]. - The funding for the offer comes from the acquirer's own funds and legally raised funds, with no involvement from the listed company or its affiliates [6][7]. Compliance and Procedures - The acquirer, Mr. Cao Fei, does not require any authorization or approval from relevant institutions to make the offer [4]. - The offer is made in compliance with the Securities Law and the Takeover Management Measures, ensuring that the offer price is based on the weighted average price of the company's shares over the previous 30 trading days [5].
“翻倍牛股”,停牌核查!
第一财经· 2025-06-11 15:58
2025.06. 11 本文字数:978,阅读时长大约2分钟 作者 | 一财资讯 6月11日晚间,*ST亚振发布公告称,公司股票于5月6日至6月11日连续二十六个交易日内日收盘价 格涨幅偏离值累计达到107.83%,多次触及股票交易异常波动。公司股票短期涨幅与同期上证指 数、家具制造业存在严重偏离。为维护投资者利益,公司将就股票交易情况进行核查。 *ST亚振公告,2025年6月10日,公司所属家具制造业最新滚动市盈率为16.00,市净率为1.89, 公司最新滚动市盈率为亏损;市净率为13.88,严重高于同行业水准。可能存在市场情绪过热,非理 性炒作情形。公司郑重提醒广大投资者,公司股价可能存在短期涨幅较大后下跌的风险,请投资者务 必充分了解二级市场交易风险,切实提高风险意识,理性决策、审慎投资。 全国已有27个省份延长婚假 截至今日收盘,*ST亚振再度涨停。该股近期表现亮眼,5月股价累计涨幅93.14%,跻身5月月度十 大牛股之列。5月6日至6月11日,*ST亚振股价累计上涨111.60%。 公告显示,公司2024年度经审计的扣除非经常性损益后的净利润为负值,且扣除与主营业务无关的 业务收入和不具备商业实质的 ...